Search Results - "Shirren, Joseph"
-
1
Pathophysiology of neratinib-induced diarrhea in male and female rats: microbial alterations a potential determinant
Published in Breast cancer (Tokyo, Japan) (2021)“…Background Neratinib is a potent irreversible pan-ErbB tyrosine kinase inhibitor, approved by the FDA for extended adjuvant treatment of HER2-positive breast…”
Get full text
Journal Article -
2
Irinotecan disrupts tight junction proteins within the gut: Implications for chemotherapy-induced gut toxicity
Published in Cancer biology & therapy (01-02-2014)“…Chemotherapy for cancer causes significant gut toxicity, leading to severe clinical manifestations and an increased economic burden. Despite much research,…”
Get full text
Journal Article -
3
Targeting neratinib-induced diarrhea with budesonide and colesevelam in a rat model
Published in Cancer chemotherapy and pharmacology (01-03-2019)“…Purpose Neratinib is an irreversible pan-ErbB tyrosine kinase inhibitor used for the extended adjuvant treatment of early-stage HER2-positive breast cancer…”
Get full text
Journal Article -
4
Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report
Published in Cancer chemotherapy and pharmacology (01-02-2017)“…Purpose Irinotecan-induced gut toxicity is mediated in part by Toll-Like receptor 4 (TLR4) signalling. The primary purpose of this preclinical study was to…”
Get full text
Journal Article -
5
Selective MMP Inhibition, Using AZD3342, to Reduce Gastrointestinal Toxicity and Enhance Chemoefficacy in a Rat Model
Published in Chemotherapy (Basel) (01-01-2018)“…The common cytotoxic mechanisms that underpin chemoefficacy and toxicity have hampered efforts to deliver effective supportive care interventions, particularly…”
Get more information
Journal Article